Vascular effects of simvastatin are similar to hormone replacement therapy in postmenopausal women.
To compare effect of six month transdermal 17 β-estradiol supplementation with oral medroxyprogresterone acetate to oral simvastatin treatment on nitric oxide (NO), endothelin-1, β-thromboglobulin, vascular endothelial growth factor (VEGF) and von Willebrand factor (vWF) levels during standard exercise test in post menopausal women. 32 women were included to the study. Group 1 treated with 17β-estradiol combined with medroxyprogesterone. Group 2 treated with simvastatin, group 3 was the controls. VEGF plasma levels as well as basal and standard exercise test induced levels of vWF, NO, endothelin- 1, β-thromboglobulin were measured at the beginning of the study, at 3rd and 6th month of the study. During standard exercise test these parameters were measured three times: at the beginning, at peak exercise and at the 15th minute of recovery. 17β-estradiol supplementation and simvastatin treatment reduced basal and exercise test induced endothelin-1 plasma level. 17β-estradiol supplementation gradually increased NO release, whereas simvastatin initially reduced and finally increased nitric oxide release. NO/ET-1 ratio was increased at peak exercise and recovery time in group 1 whereas only at peak exercise in group 2. Basal VEGF plasma level and β-thromboglobulin level at recovery time were reduced after 6 month of simvastatin therapy. Six months long oral simvastatin exerted beneficial influence on endothelial function equal to that of continuous transdermal 17β-estradiol supplementation combined with medroxyprogesterone acetate. Simvastatin only exerted benefical effect on platelet function. The protective effect of both therapies was more pronounced during exercise and recovery time.